Systematic (IUPAC) name | |
---|---|
7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Pregnancy cat. | ? |
Legal status | ℞ Prescription only |
Routes | Oral |
Identifiers | |
CAS number | 69975-86-6 |
ATC code | R03DA11 |
PubChem | CID 50942 |
UNII | MPM23GMO7Z |
KEGG | D03898 |
Chemical data | |
Formula | C11H14N4O4 |
Mol. mass | 266.25 g/mol |
SMILES | eMolecules & PubChem |
(verify) |
(what is this?)
Doxofylline (INN), (also known as doxophylline) is a xanthine derivative drug used in the treatment of asthma.[1]
It has antitussive and bronchodilator[2] effects, and acts as a phosphodiesterase inhibitor.[3]
In animal and human studies, it has shown similar efficacy to theophylline but with significantly less side effects.[4]
Unlike other xanthines, doxofylline lacks any significant affinity for adenosine receptors and does not produce stimulant effects. This suggests that its antiasthmatic effects are mediated by another mechanism, perhaps its actions on phosphodiesterase.[1]
5. Dali Shukla, Subhashis Chakraborty, Sanjay Singh & Brahmeshwar Mishra. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy. 2009; 10(14): 2343-2356, DOI 10.1517/14656560903200667, PMID 19678793
|
|
ytr